NCT05814432 - Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS | Biotech Hunter

Enrollment

279

Participants

Timeline

Start Date

January 16, 2025

Primary Completion Date

August 28, 2026

Study Completion Date

November 28, 2026

Conditions

Disseminated Histoplasma Capsulatum InfectionAIDS and InfectionsImmunosuppressionFungal Infection

Interventions

DRUG

Single high dose of liposomal amphotericin B

Single high dose (10 mg/kg) of liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS

DRUG

L-AmB standard dose

Standard treatment (3 mg/kg for two weeks) with liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS

Trial Locations (5)

RECRUITING

Hospital de Doenças Tropicais, Goiânia

RECRUITING

Hospital Giselda Trigueiro, Natal

RECRUITING

Hospital de Clinicas de Porto Alegre, Porto Alegre

RECRUITING

Hospital Geral de Roraima, Boa Vista

RECRUITING

Federal University of Health Sciences of Porto Alegre, Porto Alegre